

A facile synthesis of 1-ethoxy-4-cyano-5-ethoxycarbonyl-3*H*-azuleno[1,2-*c*]pyran-3-one, a selective 15-lipoxygenase inhibitor

Bing Bing Lin,^{a,*} Tadayoshi Morita,^a Yun-Shan Lin^a and Hui-Ling Chen^{b,*}

^aGraduate Institute of Chemistry, Tamkang University, Tamsui, Taipei (251), Taiwan

^bHepatitis Research Center, National Taiwan University Hospital, Taipei (100), Taiwan

Received 29 August 2003; revised 6 October 2003; accepted 9 October 2003

Abstract—A facile method to synthesize 1-ethoxy-4-cyano-5-ethoxycarbonyl-3*H*-azuleno[1,2-*c*]pyran-3-one, in yield of 92%, which showed selective inhibition effect on 15-lipoxygenase (soybean source) at $IC_{50} = 24.2 \pm 2.7 \mu M$ while no inhibition effect was observed at greater than 300 μM on 5-lipoxygenase, lipid peroxidase, phospholipase A₂, protein kinase C, and cyclooxygenase.

© 2003 Elsevier Ltd. All rights reserved.

Lipoxygenase (LOX) is a biological target for many diseases such as asthma, atherosclerosis, and cancer.^{1,2} LOXs are classified with respect to their positional specificity of arachidonic acid oxygenation, in particular, the reticulocyte-type 15-LOX and the human 5-LOX, are well characterized with respect to their structural and functional properties.^{3,4} Some natural azulene derivatives (chamazulene, guaiazulene) and synthetic azulene derivatives showed anti-oxidant activity and TXA₂/prostaglandin endoperoxide receptor antagonist.^{5,6} Furthermore, synthetic azulene analogues such as 3-alkyl or 3-(hydroxy)alkylazulene-1-carboxylic acids and esters showed their effects on inhibition of soybean lipoxygenase by 100% at 1 mM.⁷


Diazoquinones (diazoxides, quinone diazides) are important synthetic intermediates because of their high reactivity, photochemically and thermochemically.⁸ Among the 22 possible isomers of diazoazulenequinone (diazo-dihydro-oxoazulenes, diazoazulenequinones), the compounds of 2-D-2,6-AQ(2-diazo-2,6-azulenequinone) type are stable to be isolated while 6-D-2,6-AQ(6-diazo-2,6-azulenequinone) type are unstable to be isolated.⁹ We had reported the facile synthesis of 2-diazo-1,3-dicyano-6-oxo-2,6-dihydroazulene and the diazotization of diethyl 6-amino-2-hydroxyazulene-1,3-dicarboxylate.^{10,11} In this study, we report the synthesis of compounds of 1,2-azulenoquinone dimethide type, that is

1-ethoxy-4-cyano-5-ethoxycarbonyl-3*H*-azuleno[1,2-*c*]pyran-3-one **2**, from tropolone,^{9,12} via the corresponding diethyl 2-cyanocarbamoylmethylazulene-1,3-dicarboxylate **1**.^{13,14}

A mixture of diethyl 2-chloroazulene-1,3-dicarboxylate,¹² (918 mg, 3 mmol) malonitrile (218 mg, 3.3 mmol), anhydrous 1,2-dimethoxy ethane (8 mL), sodium hydroxide 168 mg was stirred 24 h at 25 °C for 24 h to produce red color sodium salts precipitates. The mixture was then acidified by anhydrous acetic acid, then extracted with water/chloroform. The organic layer was neutralized with sodium bicarbonate and then worked up. The residue was chromatographed on silica-gel with successive elution (500 mL each) of benzene, chloroform, and ethyl acetate to obtain product diethyl 2-cyanocarbamoylmethylazulene-1,3-dicarboxylate **1**.^{13,14}

Diethyl 2-cyanocarbamoylmethylazulene-1,3-dicarboxylate **1** (100 mg) and 3 mL acetic anhydride were used for reflux for 3 h at 110–130 °C to obtain (Scheme 1) orange-yellow needle crystal product **2**,¹⁵ with a yield of 92% via a ring closure of the neighboring groups.

Assay of 5-lipoxygenase inhibition was run using a crude enzyme preparation from rat basophilic leukemia



Scheme 1. Acylation to form 1-ethoxy-4-cyano-5-ethoxycarbonyl-3*H*-azuleno[1,2-*c*]pyran-3-one.

*Corresponding author. Tel.: +886-939398036; fax: +886-227-065261; e-mail: a332@yahoo.com

† These authors contributed equally to this work.

cells (RBL-1). Test compound was pre-incubated with the enzyme for 5 min. The reaction was initiated by addition of substrate (linoleic acid), run for 15 min, pH 7.4, at 37 °C, and then terminated by addition of 0.3 M citric acid. The levels of 5-HETE (5-mono-hydroxyeicosatetraenoic acid) was determined by means of radioimmunoassay.^{16–18}

Assay of 15-lipoxygenase (soybean source) inhibition was run using the enzyme pre-incubated with test compound for 4 min. The reaction was initiated upon the addition of substrate (linoleic acid), run for 10 min, pH 7.4, at 25 °C, and then terminated by the addition of NaOH. The formation of 15-HETE was determined by measuring absorbance at 234 nm.^{19–23}

Lipid peroxidase (from rat liver) inhibition was assayed as the followings: Microsomes were prepared from rat livers and the protein concentration was determined. A reaction mixture consisting of 2 mg protein of the microsomal preparation, a NADPH generating system, with potent peroxidation antagonists and 20 mM CCl₄ was incubated for 12 min, pH 7.4, at 37 °C. The reaction was terminated by adding a mixture of thiobarbituric acid and trichloroacetic acid, and the absorbance was read at 535 nm. The latter was proportional to the concentration of malondialdehyde.²⁴

Phospholipase A₂ (PLA₂) inhibition assay: PLA₂ (from porcine pancreas) was pre-incubated with test compound for 10 min in 0.1 M glycine–NaOH buffer, pH 9.0, at 37 °C. The reaction was initiated by addition of 0.03 μ Ci 1-palmitoyl-2-[1-¹⁴C]oleoyl-L-3-phosphatidylcholine, run for 5 min pH 9.0, at 37 °C and then terminated by adding 0.2 M EDTA. [¹⁴C]Oleate was extracted with acidic hexane, and an aliquot of the hexane layer was analyzed by scintillation counting.²⁵

Protein kinase C (from rat brain) inhibition assay: the reaction mixture (0.2 mL) contained 5 mmol Tris–HCl, 50 mg of Histon III-S, 2.5 nmol of [γ -³²P]ATP, 2.5 mmol MgCl₂, with Triton X-100, phosphatidylserine, diacylglycerol. The reaction was initiated by addition of the enzyme, run for 15 min, pH 7.5, at 25 °C, and then terminated by 75 mM cold phosphoric acid. An aliquot was removed to spot on phosphocellulose paper, then counted to determine the radioactivity of ³²P-Histone.^{26,27}

Cyclooxygenase inhibition assay: cyclooxygenase (from ram seminal vesicle) was incubated with arachidonic acid (500 μ M) for 1.5 min at 27 °C in the presence or absence of test compounds. The reaction was run for 15 min, pH 7.5, at 27 °C, then terminated by adding trichloroacetic acid. Cyclooxygenase activity was determined by reading absorbance at 532 nm.^{17,18,28,29}

Those starting, intermediate and product compounds including **1** and **2** were screened for their biological effects on the said enzyme inhibition assays. 1-Ethoxy-4-cyano-5-ethoxycarbonyl-3*H*-azuleno[1,2-*c*]pyran-3-one **2** showed selective inhibition effect on 15-lipoxygenase at IC₅₀ = 24.2 \pm 2.7 μ M (phenidone was used as a reference

compound in this 15-lipoxygenase inhibition assay and showed IC₅₀ = 2.2 \pm 0.2 μ M) while no inhibition effect was observed at greater than 300 μ M on other enzymes, such as 5-lipoxygenase, lipid peroxidase, phospholipase A₂, protein kinase C, and cyclooxygenase.

1-Ethoxy-4-cyano-5-ethoxycarbonyl-3*H*-azuleno[1,2-*c*]pyran-3-one **2**, containing the 1,2-azulenoquinone dimethide structure, showed yellow color which is different from the red-violet color of ordinary azulene compounds without 1,2-dimethide structure. By 2D NMR H–H COSY revealed that the five hydrogens on the seven-member ring were not replaced. In acid solvent CF₃COOH or CF₃COOD (TFA: trifluoroacetic acid), the UV λ_{max} of 1-ethoxy-4-cyano-5-ethoxycarbonyl-3*H*-azuleno[1,2-*c*]pyran-3-one **2** showed a strong absorbance at 477.5 nm which is quite different from that of being in neutral solvent MeOH, acetone, or CHCl₃. ¹H NMR spectra of various protons (H-6, 7, 8, 9, 10) of the compound also showed significant differences in neutral solvent if compared to that in TFA: Upfield chemical shifts with a difference of δ 0.13 (ppm) for H-7, 8, 9 (δ 8.11 in acetone-*d*₆ while δ 7.98 in CF₃COOD); with a difference of δ 0.63 (ppm) for H-6 (δ 9.34 in acetone-*d*₆ while δ 8.71 in CF₃COOD); and with a difference of δ 0.44 (ppm) for H-10 (δ 9.47 in acetone-*d*₆ while δ 9.03 in CF₃COOD). Normally a carbonium ion may cause downfield chemical shifts.⁹ Therefore, it could be attested that it is not a 14 π resonance downfield chemical shifts 13C-*O*-12 π system (13 carbons and the one oxygen in the heterocycle participating in the resonance). Those observed upfield chemical shifts were the results of 13C-12 π resonance system. The protonation provided by TFA unto the lone pair electrons of the oxygen of the pyran ring produced an enlarged 13C-12 π resonance system (without the oxygen participating in the resonance)—an peripheral condensed system with paratropic character, an anti-aromaticity 13C-12 π resonance system. Whether this characteristics be related to the said biological effects and the related in vivo effects of compound **2** needs to be further explored.

Acknowledgements

We appreciate the late Emeritus Professor Testsuo Nozoe of Tohoku University of Japan, and the Emeritus Professor Fa-Ching Chen of National Taiwan University and Tamkang University for their guidance. Heartfelt gratitude to Mr. Hsi-Lin Chen and Dr. Tsuen-Ih Ruo of MDS Panlabs Taiwan Ltd for their continuous encouragement and support.

References and notes

- Kuhn, H.; Walther, M.; Kuban, R. J. *Prostaglandins Other Lipid Mediat.* **2002**, 68–69, 263.
- Mogul, R.; Holman, T. R. *Biochemistry* **2001**, 40, 4391.
- Whitman, S.; Gezinci, M.; Timmermann, B. N.; Holman, T. R. *J. Med. Chem.* **2002**, 45, 2659.
- Tomiyama, T.; Yokota, M.; Wakabayashi, S.; Kosakai, K.; Yanagisawa, T. *J. Med. Chem.* **1993**, 36, 791.

5. Yokota, M.; Uchibori, S.; Hayashi, H.; Koyama, R.; Kosakai, K.; Wakabayashi, S.; Tomiyama, T. *Bioorg. Med. Chem.* **1996**, *4*, 575.
6. Rekka, E.; Chrysseis, M.; Siskou, I.; Kourounakis, A. *Chem. Pharm. Bull. (Tokyo)* **2002**, *50*, 904.
7. Kosakai, K.; Wakabayashi, S.; Sato, T.; Mochizuki, S.; Tomiyama, A.; Zhou, Q.; Satake, N.; Shibata, S. *J. Cardiovasc. Pharmacol.* **1993**, *21*, 441.
8. (a) Wentrup, C. In *Reactive Molecules: The Neutral Reactive Intermediate in Organic Chemistry*; Wiley: New York, 1984; p 162. (b) Regitz, M. In *The Chemistry of Diazonium and Diazo Groups*; Patai, S., Ed.; Wiley: New York, 1978; Chapter 17.
9. (a) Nozoe, T.; Asao, T.; Susumago, H.; Ando, M. *Bull. Chem. Soc. Jpn.* **1974**, *47*, 1471. (b) Nozoe, T.; Takase, K.; Tada, M. *Bull. Chem. Soc. Jpn.* **1965**, *38*, 247. (c) Morita, T.; Saito, T.; Takase, K.; Lin, Y.-S.; Tsai, P.-F.; Van H.-M.; Chen, F.-C.; Nozoe, T. *Abstracts of Papers*, 7th International Symposium on Novel Aromatic Compounds, Victoria, BC, Canada, July 1992; Abstract No. P-10. (d) Saito, M.; Morita, T.; Takase, K. *Chem. Lett.* **1974**, 955. (e) Olah, G. A.; White, A. M.; Orien, D. H. In *Carbonium Ion*; Olah, G. A., Schleyer, P. von. R., Eds.; John Wiley & Sons: New York, 1973; Vol. IV, p 1734.
10. Wun, W.-C.; Huang, T.-C.; Lin, S.-J.; Lin, B. B.; Morita, T.; Lin, Y.-S. *Journal of Chinese Chemical Society* **1993**, *40*, 593.
11. Huang, T. C.; Morita, T.; Lin, B. B.; Lin, Y.-S. *J. Chinese Chem. Soc.* **1994**, *41*, 199.
12. (a) Nozoe, T.; Seto, S.; Matsumura, S. *Bull. Chem. Soc. Jpn.* **1962**, *35*, 1990. (b) For a review on the synthesis of azulenes, see: Fleming, P. R.; Sharpless, K. B. *Chemtracts: Org. Chem.* **1988**, *2*, 205.
13. All melting points are uncorrected. IR spectra were recorded on a Perkin-Elmer IR-983G spectrophotometer. Proton nuclear magnetic resonance (^1H NMR) spectra were obtained on a Bruker AC-300 spectrometer. Tetramethylsilane (TMS) was used as an internal standard for ^1H NMR. Chemical shifts (δ /ppm) and coupling constants (Hz) were measured with respect to TMS. Mass spectra were recorded on a Finnigan TSQ-46C spectrometer at 70 eV ionizing irradiation. Higher-resolution mass spectra (HRMS) were recorded on a JEOL JMS-HX 110 spectrometer. Ultraviolet-visible spectra were recorded on Shimadzu UV-202 and UV-160 spectrometer.
14. **1**: reddish violet needles (from benzene), mp 184–185 °C; yield 1.8%; UV: λ_{max} in MeOH nm (log ϵ): 237 (4.48), 278 (4.44), 294^(sh) (4.59), 304 (4.62), 366 (3.83), 510 (2.83), λ_{max} in MeOH-aq NaOH: 226 (4.27), 380 (4.40), 494 (4.13); IR (KBr, cm^{-1}): 3460, 3195, 2242 (w), 1704, 1684, 1431, 1198. ^1H NMR (60 MHz, DMSO- d_6) δ 1.56 (6H, t, $J=7.0$ Hz, CH_3), 4.61 (4H, q, $J=7.0$ Hz, CH_2), 6.46 (s, CH), 8.00 (3H, m, H-5, 6, 7), 9.81 (2H, d, $J=11$ Hz, H-4, 8); Elem. anal. found: C, 64.68; H, 5.44; N, 7.91%; Calcd for $\text{C}_{19}\text{H}_{18}\text{N}_2\text{O}_5$: C, 64.40; H, 5.12; N, 7.91%.
15. **2**: mp 172–173 °C, orange yellow needles from EtOH, UV λ_{max} nm (log ϵ , MeOH): 235.2 (4.349), 276.2 (4.354), 301.2 (4.56), 334.6 (3.83), 363.6 (3.87), 390^(sh) (3.23), 490 (2.98), 580^(sh) (2.50). UV λ_{max} nm (log ϵ , CHCl_3): 250.2 (4.32), 325^(sh) (4.5), 340 (4.54), 410 (3.83), 430^(sh) (3.33), 600 (2.12), 640^(sh) (1.93), 680^(sh) (1.78), 715^(sh) (1.60), 760^(sh) (1.56), 784^(sh) (1.46). UV λ_{max} (log ϵ , CF_3COOH): 270 (3.81), 290 (4.05), 305^(sh) (4.27), 325.2 (4.5), 340 (4.5), 395^(sh) (3.41), 445^(sh) (3.70), 477.5 (3.95), 585^(sh) (1.90), 610^(sh) (1.76), 630^(sh) (1.70), 710^(sh) (1.51), 755 (1.46), 790 (1.40). ^1H NMR (acetone- d_6) (δ): 1.44 (3H, t, $J=7.3$ Hz, $-\text{OCH}_2\text{CH}_3$), 1.55 (3H, t, $J=7.3$ Hz, $-\text{OCH}_2\text{CH}_3$), 4.48 (2H, q, $J=6.8$ Hz, $-\text{OCH}_2\text{CH}_3$), 4.75 (2H, q, $J=6.7$ Hz, $-\text{OCH}_2\text{CH}_3$), 8.11 (3H, m, H-7, 8, 9), 9.34 (1H, dd, $J=1.2$, 11.1 Hz, H-6), 9.47 (1H, dd, $J=1.3$, 9.7 Hz, H-10); ^1H NMR (CF_3COOD) (δ): 1.69 (3H, t, $J=7.2$ Hz, $-\text{OCH}_2\text{CH}_3$), 1.84 (3H, t, $J=7.2$ Hz, $-\text{OCH}_2\text{CH}_3$), 4.69 (2H, q, $J=7.2$ Hz, $-\text{OCH}_2\text{CH}_3$), 5.18 (2H, q, $J=7.2$ Hz, $-\text{OCH}_2\text{CH}_3$), 7.98 (3H, m, H-7, 8, 9), 8.71 (1H, d, $J=11.6$ Hz, H-6), 9.03 (1H, d, $J=7.4$ Hz, H-10). ^{13}C NMR (δ): 14.32, 14.60, 60.57, 68.39, 79.05, 108.50, 114.51, 116.11, 134.53, 134.72, 136.58, 137.21, 140.84, 144.80, 148.11, 154.80, 168.13, 171.91, 202.27; IR (KBr, cm^{-1}): 2224, 1758, 1684, 1556, 1209, 1140, 1061, 1007. EIMS (20 eV) (m/z , %): 337 (M^+ , 54), 281 (24), 237 (100), 193 (33), 164 (45), 151 (19), 101 (5), 55 (20); Elem. anal. found: C, 67.91; H, 4.79; N, 4.15%; Calcd for $\text{C}_{19}\text{H}_{15}\text{NO}_5$: C, 67.65; H, 4.48; N, 4.15%. HRMS: found M^+ , 337.0933 (Calcd for $\text{C}_{19}\text{H}_{15}\text{NO}_5$: M^+ , 337.0948).
16. Samuelsson, B.; Dahlen, S.-E.; Lindren, J. A.; Bouzer, C. A.; Serhan, C. N. *Science* **1987**, *237*, 1171.
17. Egan, R. W.; Gale, P. H. *J. Biol. Chem.* **1985**, *260*, 11554.
18. Shimizu, T.; Radmark, O.; Samuelsson, B. *Proc. Natl. Acad. Sci. U.S.A.* **1984**, *81*, 689.
19. Kemal, C.; Louis-Flamberg, P.; Krupinski-Olsen, R.; Shorter, A. L. *Biochemistry* **1987**, *26*, 7064.
20. Egmond, M. R.; Brunori, M.; Fasella, P. M. *Eur. J. Biochem.* **1976**, *61*, 93.
21. Lin, B. B.; Lin, Y.-S.; Chen, K.-J.; Chen, F.-C. *Chinese Pharm. J.* **1992**, *44*, 265.
22. Lin, B. B.; Lin, Y.-S. *Chemistry Express, Kinki Chem. Soc. Jpn.* **1992**, *7*, 297.
23. Lin, B. B.; Lin, Y.-S. *Chemistry Express, Kinki Chem. Soc. Jpn.* **1993**, *8*, 21.
24. Mansey, D.; Sassi, A.; Dansette, P. M.; Plat, M. *Biochem. Biophys. Res. Commun.* **1986**, *135*, 1015.
25. Katsumata, M.; Gupta, C.; Goldman, A. S. *Anal. Biochem.* **1986**, *154*, 676.
26. Jeng, A. Y.; Sharky, N. A.; Blumberg, P. M. *Cancer Res.* **1986**, *46*, 1966.
27. Hannun, Y. A.; Loomis, C. R.; Bell, R. M. *J. Biol. Chem.* **1985**, *260*, 10039.
28. Evans, A. T.; Formukong, E. A.; Evans, F. J. *Biochem. Pharm.* **1987**, *36*, 2035.
29. Boopathy, R.; Balasubramanian, A. S. *Biochem. J.* **1988**, *239*, 371.